SCHEMBL20657462

SCHEMBL20657462

CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(NC(=O)NC(Cc3ccc(Cl)cc3)C(=O)O)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 5/20 0.58
ALDH1A1 P00352 3/20 0.53
MAPT P10636 2/20 0.53
IDH1 O75874 1/20 0.53
FPR2 P25090 3/20 0.51
KDM4E B2RXH2 1/20 0.49
KDM4A O75164 1/20 0.49
CA2 P00918 1/20 0.49
CNR1 P21554 1/20 0.49
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20657460 1.00 GHSR (0.58) GHSRALDH1A1MAPTIDH1FPR2
SCHEMBL20671467 0.85 GHSR (0.56) GHSRIDH1CNR1
SCHEMBL21935227 0.85 GHSR (0.56) GHSRIDH1CNR1
SCHEMBL20671403 0.84 GHSR (0.49) GHSRALDH1A1MAPTIDH1FPR2
SCHEMBL21935195 0.84 GHSR (0.49) GHSRALDH1A1MAPTIDH1FPR2
SCHEMBL20657527 0.82 GHSR (0.47) GHSRIDH1CNR1HDAC3HDAC4
SCHEMBL20657526 0.82 GHSR (0.47) GHSRIDH1CNR1HDAC3HDAC4
SCHEMBL20671678 0.81 CA12 (0.57) GHSRALDH1A1MAPTFPR2CA2
SCHEMBL20657685 0.79 MMP9 (0.64) ALDH1A1FPR2CA2MEN1KMT2A
SCHEMBL20657686 0.79 MMP9 (0.64) ALDH1A1FPR2CA2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200129458-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS AJINOMOTO CO., INC. (JP) 2020-04-30 US disclosed
EP-3438091-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS AJINOMOTO CO., INC. (JP) 2019-02-06 EP disclosed
US-20190022039-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS AJINOMOTO CO., INC. (JP) 2019-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200129458-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS GLP1R, GPR119, GIPR GHSR 6/4885ALDH1A1 2152/4885MAPT 4791/4885
US-20190022039-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS GLP1R, GPR119, GIPR GHSR 6/4885ALDH1A1 2152/4885MAPT 4791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.